Road rash is a colloquial term for skin injury caused by abrasion with road surfaces, often as a consequence of cycling and motorcycling accidents. It may also result from running, inline skating, roller skating, skateboarding, and longboarding accidents. The term may be applied to both a fresh injury and also to the scar tissue left by an old injury. Symptoms may include pain and heavy bleeding. Motorcyclists can reduce the risks of road rash by wearing appropriate motorcycle personal protective equipment such as a full face helmet, protective clothing, gloves, dusters and boots. Similarly, inline skaters can reduce their chance of such abrasion injuries by wearing protective knee and elbow pads. Road rash is often termed gravel rash in the United Kingdom. The term is old and is mentioned in Rudyard Kiplings Kim (1901). According to the OED it first appeared in print in the Hottens Dictionary of Modern Slang, Cant, and Vulgar Words (2nd Ed, 1860). References
External links

Abrasions and Road rash
Road rash - abrasion treatment
This structural feature and mechanism of metabolism that must occur before the drug can inhibit the enzyme explains why it has a greater duration of action than another similar drug used for the same indication, Captopril. Enalapril has a slower onset of action than Captopril but a greater duration of action. However, unlike Captopril, Enalapril does not have a thiol moiety. Medical uses
Enalapril is used to treat hypertension, symptomatic heart failure, and asymptomatic left ventricular dysfunction. ACE-inhibitors (including enalapril) have demonstrated ability to reduce the progression and worsening of existing chronic kidney disease in the presence of proteinuria/microalbuminuria (protein in the urine, a biomarker for chronic kidney disease). This renal protective effect is not seen in the absence of proteinuria/microalbuminuria, including in diabetic populations. The benefit has been particularly demonstrated in patients with hypertension and/or diabetes, and is likely to be seen in other populations (although further studies and subgroup analyses of existing studies are needed). It is widely used in chronic kidney failure. Furthermore, enalapril is an emerging treatment for psychogenic polydipsia. A double-blind, placebo-controlled trial showed that when used for this purpose, enalapril led to decreased water consumption (determined by urine output and osmolality) in 60% of patients. Pregnancy and breastfeeding
Enalapril is pregnancy category D. Some evidence suggests it will cause injury and death to a developing fetus. Patients are advised not to become pregnant while taking enalapril and to notify their doctors immediately if they become pregnant.